was treated with probucol and colestyramine for hypercholesterolemia from 1978, followed by various cholesterol lowering regimens. Ethylicosapentate, pravastatine, and colestyramine were administered from December 1996, February 1997 and March in 1997, respectively. Diltiazem, isosorbide dinitrate, and nicorandil were also given from November, 1996 because of effort angina. Magnetic resonance angiography revealed stenosis of both common carotid arteries and both vertebral arteries. Although she was asymptomatic, ticlopidine (200 mg) was prescribed on February 12, 1999 . No invasive procedures were performed. She was admitted to hospital on March 3, 1999 for further cerebrovascular and cardiac evaluation. Coronary arteriography revealed significant stenosis of the right coronary artery (RCA) and left circumflex artery. Percutaneous transluminal coronary angioplasty (PTCA) was performed on the RCA on April 13, 1999 , and aspirin (81 mg) was started the same day. Low-density lipoprotein (LDL) apheresis was started from April 26, 1999 every 2 weeks because a further reduction in the LDL-cholesterol level was recommended. She recovered well after the PTCA and LDL apheresis and was discharged on May 18, 1999.
She was readmitted on July 23, 1999 because of progressive exertional dyspnea that developed in early June. Her pulse rate was 65 beats/min, blood pressure was 138/74 mmHg and her body temperature 36.6°C. She had no skin eruptions. There were fine crackles in both lower lungs and a chest X-ray revealed a ground-glass pattern and reticulonodular infiltration, prominent at the bases, with mild cardiomegaly (Fig 1C) . A chest computed tomography (CT) scan showed interstitial infiltration in both the lower and the peripheral lung fields (Fig 2A,B) . A high resolution CT also revealed air space consolidations in the subpleural space of both lungs, consistent with BOOP (Fig 2C,D) . Her C-reactive protein level was 0.3 mg/dl and the erythrocyte sedimentation rate was slightly elevated (22 mm at 1 h and 44 mm at 2 h). White blood cells, including eosinophils, and A 67-year-old female non-smoker, who had been diagnosed with familial hypercholesterolemia associated with severe atherosclerosis of the coronary, carotid and vertebral arteries, developed interstitial pneumonia 4 months after initiating ticlopidine to inhibit platelet aggregation. The lymphocyte stimulation test by ticlopidine was positive and bronchoalveolar lavage fluid showed an increase in lymphocytes and a decrease in the CD4 + /8 + ratio, suggesting potentially undesirable side effects of ticlopidine. Two months after ticlopidine therapy was discontinued and prednisolone therapy started, the interstitial pneumonia had almost completely resolved. Two patients, one with ticlopidine-associated bronchiolitis obliterans organizing pneumonia and the other with pneumonia with multiple nodules, have been reported to date and the present patient is the third reported case of ticlopidine-induced pneumonia. renal function and autoimmune antibodies were all normal (Table 1) . Hepatic enzymes were normal, and LDH (standard range: 222-401 IU/L) was mildly increased (Table 1) . Pulmonary function tests showed a mild restrictive pattern and a moderate diffusion disorder: forced expiratory volume in 1 s (FEV1.0) of 92.0%, forced vital capacity (FVC) of 77.3%, and total gas transfer (DLco) of 49.8%. Bronchoalveolar lavage fluid (BALF) had an increase in total cells and lymphocytes (total cell count: 2.24×10 5 /ml; lymphocytes, 60%; macrophages, 30%; neutrophils, 5%; eosinophils, 5%), and a decrease in the CD4 + /8 + ratio (0.23). A transbronchoscopic lung biopsy was not done because she was still taking ticlopidine. The lymphocyte stimulation test (LST) by ticlopidine was positive compared with controls (stimulation index: 213%). Although the LST by other drugs was not performed, we suspected ticlopidineinduced interstitial pneumonia, so ticlopidine was discontinued and prednisolone (50 mg) was administered with a step-wise reduction. A chest X-ray ( Fig 1D) and CT scan (Fig 2E,F ) performed 2 months after the initiation of prednisolone showed a significant reduction of the consolidated area and another pulmonary function test revealed significant improvement (FEV1.0, 83.6%; FVC, 102.1%; DLco, 72.1%). The serum level of LDH had also normalized 1 month after ticlopidine was discontinued. The prednisolone was tapered off and stopped in November 1999, and the other drugs, except for ticlopidine, were continuously administered without recurrence of the disease for up to 15 months of follow-up.
Discussion
Interstitial pneumonia was diagnosed 5 months after initiating ticlopidine, but respiratory symptoms had occurred 4 months after the ticlopidine therapy began. The positive LST result induced by ticlopidine and the BALF findings also suggested that ticlopidine was the cause of the serious side effects, but aspirin, which was administered 2 months before interstitial pneumonia emerged, is another causative factor in the drug-induced pneumonia. However, the pneumonia resolved despite continued administration of aspirin. Although the LDL apheresis was also started 2 months before the interstitial pneumonia appeared, the possibility of this procedure as a cause can be excluded because it was consistently performed every 2 weeks without recurrence of interstitial pneumonia. Autoimmune disease was also excluded because the tests for autoimmune antibodies were all negative. On the bases of the findings, the patient was diagnosed as having interstitial pneumonia induced by ticlopidine.
The reported incidence of drug-induced lung disease is 6-7% of all drug-induced side effects in Japan, and of this 6-7%, interstitial pneumonia accounts for about 60%. 15 Many types of drugs, such as antibiotics (eg, minomycin, piperacillin, ceftazidine), anticancer agents (eg, bleomycin, methotrexate, peplomycin, cyclophosphamide), antirheumatic agents (eg, gold salts, sodium aurothiomalate), nonsteroidal anti-inflammatory agents (eg, aspirin, diclofenac), Chinese herbal medicines (eg, shousaikotou), interferons, granulocyte colony-stimulating factor (G-CSF) and antiarrythmic agents (eg, amiodarone) can cause pneumonia. 16, 17 A direct cytotoxic effect and an allergic effect may be involved in the mechanism of the lung toxicity. Bleomycin, a cytotoxic antibiotic, is typical of the agents that cause pulmonary parenchymal alterations, 16 and direct effects of superoxide 18 and cytokines, such as tumor necrosis factor alpha 19 and transforming growth factor beta, 20 are implicated. The mechanism of the allergic reaction remains unknown, but direct, metabolism-independent (without processing of haptenated protein) of drug recognition and the characterization of drug-specific T cells may be involved. 21 This only partly explains why symptoms usually recede after the causative drug is discontinued, because the hapten-modified proteins would be expected to have a long half life. 21 The present patient probably developed interstitial pneumonia as an allergic reaction to ticlopidine, because of the positive LST and the complete remission after discontinuing ticlopidine and administering prednisolone. However, antiplatelet agents, such as aspirin 22 and ticlopidine, 23 also stimulate neutrophil function and increase neutrophil activation or neutrophil adherence, suggesting a contribution of these agents to the pathogenesis of lung injury. Although the present patient did not undergo a transbronchial lung biopsy, the results of the BALF are compatible with the results reported by Komiya et al from 15 patients with drug-induced pneumonitis, 24 and the CD 4+ / 8+ ratio was also decreased in the first patient diagnosed as having ticlopidine-induced BOOP. 13 Although LST is a useful in vitro method of screening for drug allergies, the actual positive ratio varies from 43% to 95%. 25, 26 Additionally, caution is recommended when interpreting the results of a LST because a positive LST result does not indicate the drug responsible for the symptoms, only a sensitization to that drug.
The patient presented with interstitial pneumonia 4 months after the initiation of ticlopidine therapy, and the first reported patient, who was given ticlopidine of 500 mg per day, developed BOOP 1 month after initiation of the therapy. 13 The second reported patient, who was given 200 mg per day of ticlopidine, developed nodular-type pneumonia 8 months after the initiation of therapy. 14 These observations indicate that medical attention to this side effect is required for several months after the initiation of ticlopidine therapy. The 2 reported patients developed skin eruptions in addition to lung disease, 13, 14 but the present patient did not. However, the second patient had slight liver dysfunction according to the GPT and ALP levels. 14 The first report of ticlopidine-induced pneumonia was published 17 years after ticlopidine initially emerged in the Japanese market in 1981 and the reason why this serious side effect has been unreported for such a long period remains unknown. However, because ticlopidine is now frequently used to prevent thrombosis in patients with cardiovascular and cerebrovascular disease, increased awareness that it can cause interstitial pneumonia or other lung disease is paramount for the successful management and early treatment of these conditions.
